

**EORTC RADIATION ONCOLOGY GROUP MEETING,
TO BE HELD ON March 11-13, 2010
AT HOTEL CATALONIA RAMBLAS, Carrer de Pelai 28, 08001 Barcelona, Spain
A G E N D A**

Thursday, March 11

08.30 Registration desk open
 09.00 – 12.30 **ROG Steering Committee Meeting** (Room Canaletes)
 12.30 – 14.00 *Steering Committee Lunch*
 12.30 – 16.00 **QA Team Meeting** (including working lunch and tea) (Room Canaletes)
 14.00 – 15.30 **GU Working Party** (Room Flors)
 14.00 – 14.45 **Lung** (Room Estudis)
 14.45 – 15.30 **Imaging Working Party** (Room Estudis)
 15.30 – 16.00 *Tea break*
 16.00 – 17.30 **Brain** (Room Canaletes) **and Head/Neck** (Room Estudis) **Working Party meetings** in parallel

Friday, March 12

08.30 Registration Desk Open
 09.00 – 10.30 **GI** (Room Estudis/Flors/Caputxins) **and Breast** (Room Canaletes) **Working Party meetings** in parallel
 10.30 – 11.00 *Coffee break*
 11.00 – 13.00 **ROG Plenary Session** (Room Estudis/Flors/Caputxins)
 13.00 – 14.30 *Lunch break*
 14.30 – 17.30 **ROG Plenary Session** (Room Estudis/Flors/Caputxins)
 21.00 **Evening Event** (registration necessary)

Saturday, March 13

09.00 **ROG Plenary Session** (Room Estudis/Flors/Caputxins)
 10.30 – 11.00 *Coffee break*
 11.00 – 12.30/13.00 **ROG Plenary Session** (Room Estudis/Flors/Caputxins)
 13.30 – 16.30 **Kick-off meeting Head/Neck study 22071-24071** (Room Estudis/Flors/Caputxins) (sandwich lunch provided for Kick-off meeting participants)

Friday, March 12, 2010 – Plenary Session

11.00 Opening

EORTC Affairs (Chair: Vincent Grégoire, Brussels)
 HQ Report (HQ ROG Team)
 Introduction new ROG members (F. van den Bergh, Groningen)
 Accruals 2007-2009 (F. van den Bergh, H. Westenberg)

11.30 Brain Tumour Session

Chair: Damien Weber, Geneva; Sara Erridge, Edinburgh

Status of closed studies:

*26052-22053: Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma (RTOG 0525) (R. Stupp, S. Erridge)

Status of new and ongoing studies:

*22033-26033: Primary chemotherapy with temozolomide vs. radiotherapy in patients with **low grade glioma** after stratification for genetic 1p/19q loss: a phase III study. (B. Baumert, R. Stupp)

*22042-26042: Adjuvant postoperative high-dose radiotherapy for **atypical and malignant meningioma**: a phase II and observation study (D. Weber)

*26053-22054 CATNON: Concomitant TMZ/RT with or without adjuvant TMZ in anaplastic glioma without 1p/19q loss (EORTC/NCIC/RTOG/HUB) (M. van den Bent/B. Baumert)

*26071-22072: Multicentre, phase III study in Cilengitide in **newly diagnosed GBM with methylated MGMT** gene promoter (R. Stupp, S. Erridge/M. Shilkrut)

*26062-22061: Phase III study of temozolomide and radiation vs radiation alone in the treatment of **newly diagnosed GBM in elderly patients**. NCI-C /EORTC (Alba Brandes/Johan Menten)

*26081-22086: Phase III intergroup study of radiotherapy versus temozolomide versus radiotherapy with concomitant and adjuvant temozolomide for patients with **newly diagnosed 1p/19q deleted anaplastic oligodendroglioma** (Co-Del study) (W. Wick, M. van den Bent)

*26082-22081: Temozolomide (CCI-779) with concomitant RT followed by temozolomide maintenance treatment versus radiochemotherapy with concomitant and adjuvant temozolomide in subjects with **newly diagnosed GBM without methylation** of the MGMT gene promoter – phase II study (B. Baumert on behalf of W. Wick, G. Pesce)

Status of studies under development:

*22073-26072: Amino-acid PET versus CT/MRI-guided re-irradiation in patients with **recurrent GBM** – a randomized phase III study (Anca Grosu, Susan Short, Brigitta Baumert)

Report from Brain Tumour working party (D. Weber, S. Erridge)

12.30. Lung Cancer Session

Chair: C. Le Péchoux, Villejuif

Status of ongoing studies:

*08072-22074: CONVERT concurrent once daily versus radiotherapy twice daily in limited disease SCLC: a randomized phase III study (PI: C. Faivre Finn)

Report from Lung Cancer Working Party meeting (C. le Péchoux)

13.00 LUNCH BREAK

14.30 Reduction of cancer networks to abstract models for identification of therapy-predictive markers for radiotherapy (Dr. Rafael Rosell, Scientific Director of Oncology Research, Catalan Institute of Oncology, Badalona)

15.10 Head and Neck Cancer Session

Chair: W. Budach, Düsseldorf; H. Langendijk, Groningen

Status of new studies:

*22071-24071: Concomitant post-operative RT or RT-Chemo and Pamitumumab in **head and neck squamous cell carcinomas** with intermediate and high risk of local recurrence: study design (W. Budach)

Status of studies under development:

*24081-22082: Randomized phase III study of induction chemotherapy followed by radiotherapy plus cetuximab (RTC) versus RTC versus RT plus cisplatin in patients with **locoregionally advanced SCC of the head and neck** (J. Vermorken & L. Licitra for H/N Group, V. Grégoire for ROG)

Report from the Head and Neck Cancer working party (W. Budach/H. Langendijk)

15.55 GI Cancer Session

Chairs: O. Matzinger, Lausanne; P. Maingon, Dijon

PARADAC Project: pooled analysis of radiotherapy parameters in phase II and phase III trials in anal cancer (O. Matzinger)

Status of open studies:

*40054-22062: preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in **locally advanced rectal cancer** (PETACC-6) (H.J. Schmoll, K. Haustermans)

Status of studies under development:

- IMAGE 40081/22083 Imaging in **gastro-esophageal cancer** (F. Lordick, O. Matzinger)
- RTOG 0848: Gemcitabine with and without erlotinib, followed by a second randomization with and without chemoradiation as adjuvant treatment for **pancreatic head cancer**: a phase III study (K. Haustermans)

Report from the GI working party (O. Matzinger)

16.40 Quality Assurance

- QA activities in ongoing studies (E. Aird, C. Hurkmans)
- QA plans for future (C. Hurkmans, D. Weber, A. Gulyban)
- Vodca QA review platform (C. Hurkmans)
- Emmanuel van der Schueren Fellowship (P. Fenton)
- Report from QA Manager at HQ (A. Gulyban)

17.15 Report from Radiotherapy Technologists Section (F. Duclos, M. van Os)

<p>Group Dinner* Registration necessary (see ROG website)</p>
--

Saturday, March 13, 2010 – Plenary Session

09.15 Report on ROG website (A. Kuten, M. Lutsyk)

09.30 Presentation of Autumn ROG Meeting Venue (R.O. Mirimanoff, Lausanne)

09.40 Breast Cancer Session

Chair: H. Westenberg, Arnhem; A. Kuten, Haifa

Status of ongoing studies :

*10981/22023 AMAROS: after mapping of the axilla radiotherapy or surgery (G. van Tienhoven)

*22051-10052 SUPREMO: phase III randomized trial to assess the role of adjuvant chest wall irradiation in **“intermediate risk” operable breast cancer** following mastectomy (Joint study with MRC, BIG and Scottish Cancer Trials Breast Group (G. van Tienhoven)

*22085/10083 (EORTC/BOOG/TROG/BIG study): Randomized phase III study of radiation doses and fractionation schedules for **DCIS of the breast** (H. Westenberg)

Studies under development

*10096/22093 POWER: Positive sentinel node: wait and see versus excision or radiotherapy (J. van der Hage)

Report from Breast Cancer working party (H. Westenberg)

10.25 Coffee Break

10.50 From EPOD to PRC: from idea to clinical study (C. Liberatoscioli)

11.00 Genito Urinary Cancer Session

Chair: C. Scrase, Ipswich; F. van den Bergh (Groningen)

Status of closed studies:

*22911: phase III study in postoperative external radiotherapy in **pathological stage T2N0 prostatic carcinoma** (M. Bolla): Update of results (L. Collette, M. Bolla)

*22991: phase III study in 3D CRT alone versus 3D CRT plus adjuvant hormonal therapy in **localized T1b-c, T2a-b, N0, M0 prostatic carcinoma** (M. Bolla)

Status of ongoing studies:

*22043/30041: Post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus postoperative external radiotherapy alone in **pathological stage T3a-b, R0-1, N-/pT2R1N0, Gleason score 5-10 prostatic carcinoma**. A phase III study (M. Bolla)

Report from the Genito-urinary Cancer working party (C. Scrase, F. van de Bergh)

11.45 Lymphoma and Soft Tissue Sarcoma

Chair: P. Poortmans, Tilburg

Status of closed studies:

*20971/22997: phase III randomized study on low-dose total body irradiation and involved field radiotherapy in patients with localized **low grade non-Hodgkin's lymphoma** (M. Beijert, P. Poortmans)

Status of ongoing studies:

*20051: H10 EORTC/GELA randomized intergroup trial on early FDG-PET scan-guided treatment adaptation versus standard combined modality treatment in patients with **supradiaphragmatic stage I/II Hodgkin's Lymphoma** (P. Poortmans, Tilburg)

Status of studies under development:

*62092/22092: Phase III randomized study of preoperative radiation plus surgery versus surgery alone for patients with **retroperitoneal sarcomas** (S. Bonvalot, Villejuif; C. Le Péchoux, Villejuif)

± 12.30 Meeting closure

13.30 – 16.30

Kick-off meeting of the 22071-24071 study (Adjuvant Head and Neck)

Working Party Meeting Agendas

March 11: 14.00 hrs

<p>14.00 – 14.45 Lung Cancer Working Party Meeting (Room Estudis) <i>(Chair: C. le Péchoux)</i></p> <p>Discussions and proposals for new studies</p> <ol style="list-style-type: none">1. Randomized phase III study of PCI vs no PCI for NSCLC not suitable for radical treatment (08093-22091)2. Stage III NSCLC: After publication of the meta-analysis on combined CT-RT3. Proposal for a new trial : 3-arm trial establishing a standard CTRT regimen4. Proposal for a new PCI study in small cell lung cancer: PCI combined with neuroprotectors5. Discussions <p>Proposals for a new chair of the Lung Working Party</p>	<p>14.00 – 15.30 (Room Flors)</p> <p>GU Cancer Working Party</p> <p><i>(Chairs: C. Scrase, A.C.M. van den Bergh)</i></p> <ol style="list-style-type: none">1. Updated results of 22911 (L. Collette)2. High risk localised prostate cancer trial using concurrent and adjuvant docetaxel (M. Bolla)3. Radical radiotherapy in metastatic prostate cancer: update (D. Berthold)4. DR/QA 22043 (P. Fenton)5. New study proposals (F. van den Bergh/C. Scrase)
<p>14.45 – 15.30 Imaging Working Party Meeting (Room Estudis) <i>(Chair: U. Nestle)</i></p> <ol style="list-style-type: none">1. Introduction on planned structure of the EORTC imaging group2. Discussion of some ongoing studies with imaging in radiation oncology3. Discussion of proposed protocols4. Brainstorming: input of ROG into new EORTC Imaging Group (IG)	

15.30 – 16.00 TEA BREAK

<p>16.00 – 17.30 Brain Tumour Working Party (Room Canaletes) (Chairs: D. Weber, S.Erridge)</p>	<p>16.00 – 17.30 Head/Neck Cancer Working Party (Room Estudis) (Chairs : W. Budach, J. Langendijk)</p>
<ol style="list-style-type: none"> 1. Observation versus local EBRT alone for good prognosis patients with a solitary brain metastasis from a solid tumor after complete surgical resection: a phase III study – discussion of new ROG proposal (S. Erridge, D. Weber) 2. Prognostic value of rCBV (F. Dhermain) 3. 22073-26072 recurrent glioma: status of proposal (A. Grosu) 4. Educational session: “Read it before your medical oncologist”: landmark papers in 2010 in Neuro-Oncology (S. Erridge, D. Weber) 5. QA report Brain Studies (A. Gulyban) 6. Other business 7. Summary 	<ol style="list-style-type: none"> 1. Update: 22071-24071 Concomitant post-operative RT or RT-CH and panitumumab in high risk patients: study initiation (W. Budach) 2. Update 24081-22082: randomized phase III study of induction chemotherapy followed by radiotherapy plus cetuximab (RTC) versus RTC versus RT plus cisplatin in patients with locoregionally advanced SCC of the head and neck (V. Grégoire) 3. Larynx preservation strategies (J.A. Langendijk)

March 12: 09.00 -10.30

<i>GI Tract Working Party (Room Estudis/Flors/Caputxins)</i> <i>(Chair: O. Matzinger, P. Maingon)</i>	<i>Breast Cancer Working Party (Room Canaletes)</i> <i>(Chair: H. Westenberg, A. Kuten)</i>
<ul style="list-style-type: none"> • Discussion of a proposal for a phase II study for patients with locally advanced rectal cancer M0, defined at NMR as CRM \leq 2 mm. (J.F. Bosset) • Status of PETACC-6 (K. Haustermans) • IMAGE: 40081 (O. Matzinger) • Pancreas study 40084/RTOG 0848 (K. Haustermans) • PARADAC: Meta-analysis of anal cancer studies (O. Matzinger) 	<ul style="list-style-type: none"> ▪ Update AMAROS (G. van Tienhoven) ▪ Update SUPREMO (N. Russell) ▪ 22085/10083 DCIS boost study – status (H. Westenberg) ▪ 10096/22093 POWER: Positive sentinel node – wait and see vs excision or radiotherapy (ROG members of the writing committee) ▪ Optimal locoregional treatment in M1 patients ▪ IRMA (A. Kuten) Prophylactic contralateral breast irradiation in BRCA 1-2 pts undergoing CBT for early breast cancer - an Israeli national phase II study (A. Kuten)